We are live on ! Find out more
Macquarie Group

Macquarie Group Portfolio holdings

AUM $16.8B
1-Year Est. Return 27.39%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+27.39%
3 Year Est. Return
+81.07%
5 Year Est. Return
+109.03%
10 Year Est. Return
+396.55%
AUM
$84.7B
AUM Growth
+$3.15B
Cap. Flow
-$3.2B
Cap. Flow %
-3.77%
Top 10 Hldgs %
10.93%
Holding
2,264
New
35
Increased
617
Reduced
853
Closed
525

Top Buys

Rank Stock Value
1
LHX icon
L3Harris
LHX
+$128M
2
DHR icon
Danaher
DHR
+$114M
3
ZBRA icon
Zebra Technologies
ZBRA
+$112M
4
AIZ icon
Assurant
AIZ
+$92.7M
5
EXC icon
Exelon
EXC
+$92.2M

Sector Composition

Rank Sector Weight
1 Technology 21.36%
2 Healthcare 15.17%
3 Financials 13.51%
4 Industrials 10.72%
5 Consumer Discretionary 9.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HAPN
1476
Happen Inc
HAPN
$2.08B
$437K ﹤0.01%
49,677
-38,974
-44% -$402K
UVE icon
1477
Universal Insurance Holdings
UVE
$1.16B
$437K ﹤0.01%
41,300
XLB icon
1478
State Street Materials Select Sector SPDR ETF
XLB
$8.64B
$425K ﹤0.01%
10,930
SEDG icon
1479
SolarEdge
SEDG
$2.59B
$409K ﹤0.01%
1,444
+317
+28% +$84.1K
LSXMK
1480
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
$405K ﹤0.01%
13,359
LBTYA icon
1481
Liberty Global Class A
LBTYA
$3.31B
$399K ﹤0.01%
21,058
-5,378
-20% -$97.9K
GTY
1482
Getty Realty Corp
GTY
$2.1B
$396K ﹤0.01%
11,702
-2,736
-19% -$86.3K
TWLO icon
1483
Twilio
TWLO
$29.1B
$395K ﹤0.01%
8,061
-8,589
-52% -$489K
TEVA icon
1484
Teva Pharmaceuticals
TEVA
$35.9B
$393K ﹤0.01%
43,140
+6,483
+18% +$56.6K
SIRI icon
1485
SiriusXM
SIRI
$10B
$390K ﹤0.01%
6,671
-7,613
-53% -$468K
XPEV icon
1486
XPeng
XPEV
$11.8B
$389K ﹤0.01%
39,163
ERO icon
1487
Ero Copper
ERO
$2.71B
$382K ﹤0.01%
+27,737
New +$343K
RVTY icon
1488
Revvity
RVTY
$12.3B
$382K ﹤0.01%
2,721
+158
+6% +$21.3K
SNBR
1489
DELISTED
Sleep Number
SNBR
$379K ﹤0.01%
14,600
-855
-6% -$26K
VFC icon
1490
VF Corp
VFC
$6.68B
$379K ﹤0.01%
13,712
+3,369
+33% +$99K
IVT icon
1491
InvenTrust Properties
IVT
$2.84B
$372K ﹤0.01%
18,724
+2,900
+18% +$69.2K
VEA icon
1492
Vanguard FTSE Developed Markets ETF
VEA
$226B
$372K ﹤0.01%
8,860
-25,410
-74% -$1.03M
RPRX icon
1493
Royalty Pharma
RPRX
$26.1B
$364K ﹤0.01%
9,223
+2,145
+30% +$89.5K
IOVA icon
1494
Iovance Biotherapeutics
IOVA
$2.23B
$361K ﹤0.01%
56,509
-7,347
-12% -$57.4K
BRO icon
1495
Brown & Brown
BRO
$22.9B
$361K ﹤0.01%
6,336
-1,235
-16% -$72.2K
ALEX
1496
DELISTED
Alexander & Baldwin
ALEX
$360K ﹤0.01%
19,231
-5,862
-23% -$111K
VEON icon
1497
VEON
VEON
$3.53B
$359K ﹤0.01%
29,291
QGEN icon
1498
Qiagen
QGEN
$8.53B
$355K ﹤0.01%
6,704
+3,944
+143% +$194K
ENB icon
1499
Enbridge
ENB
$124B
$349K ﹤0.01%
8,937
AVIR icon
1500
Atea Pharmaceuticals
AVIR
$379M
$337K ﹤0.01%
70,000
-1,504
-2% -$7.61K

Similar funds

Macquarie Group's Q4 2022 Portfolio in Review

As of Q4 2022, Macquarie Group held 2,264 positions worth $84.7B, up 3.9% from $81.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Macquarie Group withdrew a net $3.2B in Q4 2022, closing 525 positions and reducing 853 holdings. Its most notable exit was Abiomed Inc, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Macquarie Group opened a new position in iShares 0-5 Year Investment Grade Corporate Bond ETF worth $58.3M.

  • Macquarie Group's largest Q4 2022 buy was iShares 0-5 Year Investment Grade Corporate Bond ETF: 1,218,670 shares worth $58.3M.
  • Macquarie Group added most to L3Harris in Q4 2022, an estimated $128M increase.
  • Macquarie Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $189M.
  • Macquarie Group fully exited Abiomed Inc in Q4 2022, selling an estimated $124M.
  • Macquarie Group's ten largest holdings make up 11% of its $84.7B portfolio in Q4 2022.
  • Macquarie Group opened 35 new positions and closed 525 in Q4 2022.
  • Macquarie Group's portfolio value rose 3.9% quarter-over-quarter to $84.7B.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.